Evidence map›Paper›PMID 30685525›Full record

ArticleEuropean journal of medicinal chemistry2019

Benzimidazolone-based selective σ

Sebastiano Intagliata, Walid F Alsharif, Christophe Mesangeau, Nicola Fazio, Michael Seminerio, Yan-Tong Xu, Rae R Matsumoto, Christopher R McCurdy

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Screening of σJournal of medicinal chemistry · 2022
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. RSC medicinal chemistry · 2021
    Review
  9. Exploring 1-adamantanamine as an alternative amine moiety for metabolically labile azepane ring in newly synthesized benzo[Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2020
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sebastiano IntagliataDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA.
Walid F AlsharifDepartment of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, Mississippi, 38677, USA.
Christophe MesangeauDepartment of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, Mississippi, 38677, USA.
Nicola FazioDepartment of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, Mississippi, 38677, USA.
Michael SeminerioDepartment of Basic Pharmaceutical Sciences, West Virginia University, Morgantown, WV, 26506, USA.
Yan-Tong XuDepartment of Basic Pharmaceutical Sciences, West Virginia University, Morgantown, WV, 26506, USA.
Rae R MatsumotoDepartment of Basic Pharmaceutical Sciences, West Virginia University, Morgantown, WV, 26506, USA; College of Pharmacy, Touro University California, Vallejo, CA, 94592, USA.
Christopher R McCurdyDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA; Department of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, Mississippi, 38677, USA. Electronic address: CMccurdy@cop.ufl.edu.
University of Mississippi · USWest Virginia University · USUniversity of Florida · US

Funding

Synthesis &Evaluation of Cocaine AntagonistsR01DA013978 · NIDA · WEST VIRGINIA UNIVERSITY · PI MATSUMOTO, RAE R · 2001 to 2010
$1.9M
Novel Pharmacologic Interventions for Drugs of AbuseR01DA023205 · NIDA · UNIVERSITY OF MISSISSIPPI · PI MCCURDY, CHRISTOPHER R · 2007 to 2011
$1.7M
NIDA NIH HHS R01 DA013978NIDA NIH HHS R01 DA023205
6 · The paper itself

Abstract

Sigma receptors (σRs) are considered to be a significant and valid target for developing new medications to address several diseases. Their potential involvement in numerous central nervous system disorders, neuropathic pain, addiction, and cancer has been extensively reported. In particular, the σ

Indexed as

LigandsAnimalsBenzimidazolesCocaine-Related DisordersHumansProtein BindingRadioligand AssayReceptors, sigmaSeizuresStructure-Activity RelationshipSubstance-Related DisordersBenzimidazolesbenzimidazoloneLigandsReceptors, sigmaBenzimidazoloneCocaine-induced convulsionsCocaine's toxicitySigma-2 ligandsSigma-2 receptorsSigma receptorsStructure-affinity relationships

Identifiers

PMID30685525
PMCPMC6369001
OpenAlexW2909892968

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.